3 November 2017

ResApp Health AGM – CEO and Managing Director's Address to Shareholders

Good morning ladies and gentlemen.

Welcome to our third annual general meeting as ResApp Health Limited.

Since our last AGM we have faced some challenges, however I am pleased that we are now standing on a solid platform with a clear path forward. Financial year 2017 was a productive year with continued progress in our Australian clinical studies, reaffirming our confidence in the performance of our technology – today, we stand behind our Australian clinical study results as the truest representation of our technology's performance.

Our headline clinical study, the SMARTCOUGH-C US paediatric study, however met with challenges and proved to be neither an accurate nor reliable evaluation of our technology due to issues directly related to study execution. In the three months following the study conclusion we have developed a detailed understanding of these issues and, in conjunction with our study partners, we have designed a robust follow-on study which is expected to begin before the onset of the US winter. We are grateful to the principal investigators at the study sites for their continued support and are pleased to again be working with same three top-tier US hospitals.

There have been significant learnings from the study and we have integrated these into the revised study. Our strengthened clinical advisory board, led by Dr Abeyratne, and the principal investigators at the hospitals have been instrumental in these revisions.

During the follow-on study we will be significantly increasing the training and oversight of the data collectors who record the cough sounds of patients. The data collection teams will use an updated smartphone app which incorporates built-in checklists, automatic background noise estimation and additional visual aids to eliminate inappropriate collection of cough data with unacceptable levels of background noise.

We are pleased with the significant improvements that have been made to the algorithms which overcome many of the issues identified in the SMARTCOUGH-C recordings. Finally, every single cough sound collected will be quality checked on site within days of its recording to ensure that all of the data used to subsequently analyse the performance of the algorithm is uncorrupted and high fidelity.

We are also improving the consistency of the clinical adjudication process with clinical adjudicators to apply a tightened set of clinical case definitions specifically designed to reduce the subjectivity of the clinical diagnosis. The adjudicators will be trained and tested on these case definitions using data from the SMARTCOUGH-C study. They will focus on providing a diagnosis consistent with the signs and symptoms at the time of recording, taking into account any response to treatment.

After multiple meetings with the principal investigators and our Australian clinical teams we now have a clear path forward for the follow-on study and look forward to enrolling patients shortly.

We have accelerated our European (CE) and Australian regulatory filings by reconfiguring our Australian paediatric clinical studies to provide the required data. Since early this year, our Australian studies have been run in a double-blind, prospective manner. We are working with the health researchers at Curtin University to provide independent statistical analysis of those studies. We are pleased with the recruitment in these studies and will provide an update shortly.

We also plan to announce additional results from our Australian adult clinical studies shortly. These results will provide the platform for ResApp, the team at The University of Queensland and our Australian clinical teams to finalise the design of our adult clinical program, including a clinical study to provide data for an adult US FDA submission. Our Australian adult study has also transitioned to a double-blind, prospective study.

The next twelve months will be exciting for ResApp and our shareholders. Lessons from our previous US study have been learnt and we expect to begin recruitment of patients in our refined US paediatric clinical study shortly. By mid next year, we expect this study to provide the clinical data for our US FDA submission. Our Australian paediatric study is recruiting patients and will provide the clinical data for our CE and TGA submissions. Our adult clinical program is progressing well and we look forward to progressing towards FDA, CE and TGA submissions for adults in 2018.

Our disciplined approach to cash management has left us well-funded to complete our clinical programs.

While our focus today is on our clinical programs, the commercial opportunities in front of us are still large. To our knowledge, we are the only company with the ability to deliver remote diagnosis of respiratory disease using only a smartphone without the need for additional hardware. Telehealth is still one of the fastest growing areas of healthcare in the US and Europe, and increasingly in Asia. Health spending continues to increase, with US healthcare spending accounting for 17.8% of US GDP in 2015 and projected to reach nearly 20% of GDP by 2020. Healthcare payers are on the constant lookout for digital health products that provide real actionable clinical insight at lower costs. We believe that our technology fits this paradigm extremely well as it provides a clear diagnostic result to clinicians for many diseases where there are no ‘gold standard’ tests and traditional methods are neither accurate nor timely. We have discussions open with multiple potential commercial partners and look forward to progressing these in 2018.

A huge thank you to our team, which includes our employees, Dr Abeyratne and his team at The University of Queensland, our scientific advisory board members and the clinical teams at our study sites. In a challenging year the team have come together and are working exceptionally hard to make ResApp a success.

Finally I would like to thank our shareholders for your support, we look forward to continuing this journey with you.

Tony Keating, CEO and Managing Director

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director and Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au